| __timestamp | Amicus Therapeutics, Inc. | Amneal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 84615000 |
| Thursday, January 1, 2015 | 47269000 | 109679000 |
| Friday, January 1, 2016 | 71151000 | 118757000 |
| Sunday, January 1, 2017 | 88671000 | 109046000 |
| Monday, January 1, 2018 | 127200000 | 230435000 |
| Tuesday, January 1, 2019 | 169861000 | 289598000 |
| Wednesday, January 1, 2020 | 156407000 | 326727000 |
| Friday, January 1, 2021 | 192710000 | 365504000 |
| Saturday, January 1, 2022 | 213041000 | 399700000 |
| Sunday, January 1, 2023 | 275270000 | 429675000 |
Cracking the code
In the competitive landscape of pharmaceuticals, understanding the financial dynamics of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Amneal Pharmaceuticals, Inc. and Amicus Therapeutics, Inc. from 2014 to 2023. Over this period, Amneal consistently outpaced Amicus in SG&A spending, with a notable increase of approximately 400% from 2014 to 2023. In contrast, Amicus saw a more modest rise of around 1,200% in the same timeframe. This disparity highlights Amneal's aggressive investment in operational activities, potentially reflecting a strategy focused on rapid expansion and market penetration. Meanwhile, Amicus's steady growth in expenses suggests a more conservative approach, possibly prioritizing sustainable development. These trends offer valuable insights into each company's strategic priorities and market positioning, providing investors and industry analysts with a clearer picture of their financial health and future prospects.
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and Amicus Therapeutics, Inc.
Takeda Pharmaceutical Company Limited and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Amneal Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Amneal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Viatris Inc. vs Amicus Therapeutics, Inc. Trends and Insights
Selling, General, and Administrative Costs: Intra-Cellular Therapies, Inc. vs Amneal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Bio-Techne Corporation vs Amneal Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Jazz Pharmaceuticals plc vs Amicus Therapeutics, Inc.
Amneal Pharmaceuticals, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Viking Therapeutics, Inc. or Amicus Therapeutics, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Amicus Therapeutics, Inc. vs Catalyst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Amicus Therapeutics, Inc. and Novavax, Inc.